A phase II study of autologous regulatory T-cell (Treg) therapy in kidney transplant recipients

Trial Profile

A phase II study of autologous regulatory T-cell (Treg) therapy in kidney transplant recipients

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2016

At a glance

  • Drugs CD4+ CD25+ Treg cells (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 May 2016 New trial record
    • 29 Apr 2016 According to a Tract Therapeutics media release, the company has received Food and Drug Administration (FDA) approval to initiate this trial and patient enrollment is expected to initiate in a few months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top